Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myfemella
- Development stage
- Unknown
- Lead developer
- biosyn Arzneimittel
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Myfemella is a dietary supplement developed by biosyn Arzneimittel GmbH, specifically formulated to support bladder health. It features a quadruple combination of active ingredients: sporebiotics (*Bacillus subtilis natto* and *Bacillus coagulans*), cranberry extract (500 mg), goldenrod extract (6 mg), and lactoferrin (100 mg). The sporebiotics are bacterial cultures in spore form, which provide high stability against stomach acid, ensuring they reach the intestines effectively to modulate the microbiome. Cranberry extract is included for its proanthocyanidins, which are traditionally used to inhibit bacterial adhesion in the urinary tract, while goldenrod extract provides diuretic and anti-inflammatory support. Lactoferrin, an iron-binding protein, acts as an antimicrobial agent by sequestering iron required for bacterial growth. It is marketed as a vegetarian, lactose-free, and gluten-free tablet available over-the-counter in German pharmacies.
- Brand names
- Myfemella
02
Targets
P fimbriae
Beyond the preview
Go deeper on Myfemella.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myfemella.